Size | Price | |
---|---|---|
Other Sizes |
Additional Infomation |
Pyrimidine is the parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions. It has a role as a Daphnia magna metabolite. It is a member of pyrimidines and a diazine.
Pyrimidine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Pyrimidine has been reported in Homo sapiens, Panax ginseng, and other organisms with data available. Pyrimidine is one of two classes of heterocyclic nitrogenous bases found in the nucleic acids DNA and RNA: in DNA the pyrimidines are cytosine and thymine, in RNA uracil replaces thymine. Pyrimidine Dimer is a pair of pyrimidine bases (thymine or cytosine in DNA or uracil in double-stranded RNA) within a nucleic acid covalently linked by a cyclobutane ring, the formation of which was induced by exposure to ultraviolet radiation. The presence of pyrimidine dimers inhibits DNA replication; improper repair of these lesions promotes DNA mutagenesis. See also: Thymine (has subclass); Uracil (has subclass); Cytosine (has subclass). |
---|
Molecular Formula |
C4H4N2
|
---|---|
Molecular Weight |
80.0880
|
Exact Mass |
80.037
|
CAS # |
289-95-2
|
Related CAS # |
190201-51-5
|
PubChem CID |
9260
|
Appearance |
Colorless to light yellow <22°C powder,>22°C liquid
|
Density |
1.1±0.1 g/cm3
|
Boiling Point |
122.4±9.0 °C at 760 mmHg
|
Melting Point |
19-22 °C(lit.)
|
Flash Point |
31.1±0.0 °C
|
Vapour Pressure |
16.8±0.2 mmHg at 25°C
|
Index of Refraction |
1.503
|
LogP |
-0.33
|
Hydrogen Bond Donor Count |
0
|
Hydrogen Bond Acceptor Count |
2
|
Rotatable Bond Count |
0
|
Heavy Atom Count |
6
|
Complexity |
32.5
|
Defined Atom Stereocenter Count |
0
|
SMILES |
N1C([H])=NC([H])=C([H])C=1[H]
|
InChi Key |
CZPWVGJYEJSRLH-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C4H4N2/c1-2-5-4-6-3-1/h1-4H
|
Chemical Name |
pyrimidine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~1248.60 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (31.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (31.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (31.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 12.4860 mL | 62.4298 mL | 124.8595 mL | |
5 mM | 2.4972 mL | 12.4860 mL | 24.9719 mL | |
10 mM | 1.2486 mL | 6.2430 mL | 12.4860 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04802707 | RECRUITING | Combination Product: deoxycytidine and deoxythymidine | Mitochondrial DNA Depletion Mitochondrial Diseases Mitochondrial Encephalomyopathy Mitochondrial Encephalopathy Mitochondrial Metabolism Disorders |
McGill University HealthCentre /Research Institute of the McGill University Health Centre |
2021-10-18 | Phase 2 |
NCT03532633 | UNKNOWN STATUS | Procedure: cord blood Procedure: blood sample infant Procedure: blood sample mother Procedure: breast milk |
Prematurity | University Hospital Tuebingen | 2017-03-01 | |
NCT03982680 | UNKNOWN STATUS | Drug: Toripalimab Drug: Gemcitabine Drug: 5- fluorine pyrimidine |
Advanced Cholangiocarcinoma | Jiangmen Central Hospital | 2019-07-13 | Phase 2 |
NCT05007678 | COMPLETED | Drug: leflunomide | COVID-19 | Ashford and St. Peter's Hospitals NHS Trust | 2020-09-16 | Phase 3 |
NCT01291407 | COMPLETED | Drug: S-1 Drug: S-1 Drug: S-1 |
Gastric Cancer Gastrointestinal Neoplasms |
Chinese Academy of Medical Sciences | 2010-11 | Phase 1 |